Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome
Authors:
- Alessandro CiavarellaACAlessandro Ciavarella
- Luciano BaroncianiLBLuciano Baronciani
- Omid SeidizadehOSOmid Seidizadeh
- Paola ColpaniPCPaola Colpani
- Daniele CattaneoDCDaniele Cattaneo
- Maria Teresa PagliariMPMaria Teresa Pagliari
- Addolorata TrumaATAddolorata Truma
- Alessandra IurloAIAlessandra Iurlo
- Simona Maria SiboniSSSimona Maria Siboni
- Flora PeyvandiFPFlora Peyvandi
Open Access
- 10 June 2026
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (9) , 2147-2156
Abstract
Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associated with systemic diseases, particularly lymphoproliferative disorders (LPDs) and myeloproliferative neoplasms (MPNs). In this single‐center, retrospective cross‐sectional study, we included patients diagnosed with AVWS at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center between April 2014 and March 2025. Bleeding severity was assessed using the ISTH‐BAT score. Laboratory tests included FVIII:C, VWF:Ag, VWF:GPIbR, VWF:RCo, VWF:CB, VWFpp, and multimer analysis. Among 140 patients, 106 (76%) had MPNs and 26 (19%) LPDs. At least one bleeding symptom was observed in 70% of patients, with clinically significant bleeding occurring in 24% of the cohort. Clinically relevant bleeding (mainly mucocutaneous and gastrointestinal) was more frequent and severe in LPDs (58%) than in MPNs (13%). LPDs showed severe VWF functional defects, marked HMWM loss, and elevated VWFpp/VWF:Ag ratios (median 6.7), consistent with accelerated clearance. MPNs displayed mild HMWM reduction, normal clearance (median VWFpp/VWF:Ag ratio 1.0), and an inverse correlation between platelet count and the degree of HMWM depletion (ρ = −0.48, p < 0.001). Bleeding severity correlated inversely with VWF:GPIbR in LPDs (ρ = −0.50, p = 0.02) and with VWF:RCo in MPNs. Anti‐VWF antibodies were found in 30% of tested LPDs or autoimmune cases. The two main phenotypes presented in AVWS were immune‐mediated in LPDs and platelet‐mediated in MPNs. Understanding the underlying mechanism is crucial for accurate diagnosis and targeted treatment to reduce bleeding risk and improve outcomes.Keywords
Funding Information
- Ministero della Salute
This publication has 28 references indexed in Scilit:
- “The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study”: replyJournal of Thrombosis and Haemostasis, 2024
- Genetic determinants of enhanced von Willebrand factor clearance from plasmaJournal of Thrombosis and Haemostasis, 2023
- Acquired von Willebrand syndrome: Five cases report and literature reviewThrombosis Research, 2022
- Evaluation of a semi‐automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European CentersResearch and Practice in Thrombosis and Haemostasis, 2018
- Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia veraEuropean Journal of Internal Medicine, 2017
- Optimal Perceived Timing: Integrating Sensory Information with Dynamically Updated ExpectationsScientific Reports, 2016
- A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand SyndromeThrombosis Research, 2014
- Acquired von Willebrand Syndrome: An Underdiagnosed and Misdiagnosed Bleeding Complication in Patients With Lymphoproliferative and Myeloproliferative DisordersSeminars in Hematology, 2006
- Acquired von Willebrand Syndrome: Its Pathophysiology, Laboratory Features and ManagementJournal of Thrombosis and Thrombolysis, 2003
- Acquired von Willebrand DiseaseMayo Clinic Proceedings, 2002